The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 31, 2011

Filed:

Apr. 26, 2007
Applicants:

Dan Niculescu-duvaz, Sutton, GB;

Caroline Joy Springer, Sutton, GB;

Richard Malcolm Marais, London, GB;

Harmen Dijkstra, Maarssen, NL;

Delphine Menard, Sutton, GB;

Ion Niculescu-duvaz, Sutton, GB;

Lawrence Davies, Sutton, GB;

Arnaud Nourry, Sutton, GB;

Inventors:

Dan Niculescu-Duvaz, Sutton, GB;

Caroline Joy Springer, Sutton, GB;

Richard Malcolm Marais, London, GB;

Harmen Dijkstra, Maarssen, NL;

Delphine Menard, Sutton, GB;

Ion Niculescu-Duvaz, Sutton, GB;

Lawrence Davies, Sutton, GB;

Arnaud Nourry, Sutton, GB;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 43/42 (2006.01); A01N 43/40 (2006.01); A01N 43/52 (2006.01); A61K 31/44 (2006.01); A61K 31/415 (2006.01); C07D 513/02 (2006.01); C07D 515/02 (2006.01); C07D 403/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5 b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.


Find Patent Forward Citations

Loading…